Prospective study of allogeneic transplantation for lower risk MDS with high risk features

Question Title

* 1. How many patients with lower risk MDS (IPSS-R <3.5) do you see at your centre per year?

Question Title

* 2. Are MDS patients currently assessed for any recurrent myeloid mutations as part of routine diagnostic work up?

Question Title

* 3. Would you considering referring the following MDS patients for entry into a prospective transplant study? Patients with lower-risk MDS defined as IPSS-R very low, low and intermediate risk score (<3.5) and one or more of the following features:

Transfusion dependent requiring red cells or platelets (defined according to IWG criteria)

Thrombocytopenia with platelets < 50x10^9/L

Neutrophil count of <0.5x10^9/L non-responsive to GCSF

Intermediate or poor risk cytogenetics

Presence of at least 1 poor risk molecular feature including ASXL1, RUNX1, TP53, JAK2, U2AF1, EZH2, RAS pathway mutations (NRAS, KRAS, CBL, PTPN11, NF1, R1T1, FLT-3 or cKIT) or two or more somatic mutations

MDS with 5q- failing lenalidomide

Patients with BM fibrosis and MDS

None of the above

Question Title

* 4. If none of the above, could you explain?

Question Title

* 5. If so how many patients per year would you estimate fit these criteria at your centre?

Question Title

* 6. Does your centre have access to iron chelation?

Question Title

* 7. If so does your centre routinely iron chelate low-risk MDS patients?

Question Title

* 8. Would a low-risk MDS study compete with any others at your centre? (This study would be designed to capture those MDS patients NOT eligible for COSI/AMADEUS). If yes, which studies?

Question Title

* 9. Do you see any specific challenges (other than recruitment), related to a low-risk MDS transplant study? Are there centre-specific issues we should be aware of, or other comments? If yes, please explain.

Prospective study of allogeneic transplantation for lower risk MDS with high risk features

Question Title

* 1. How many patients with lower risk MDS (IPSS-R <3.5) do you see at your centre per year?

Question Title

* 2. Are MDS patients currently assessed for any recurrent myeloid mutations as part of routine diagnostic work up?

Question Title

* 3. Would you considering referring the following MDS patients for entry into a prospective transplant study? Patients with lower-risk MDS defined as IPSS-R very low, low and intermediate risk score (<3.5) and one or more of the following features:

Question Title

* 4. If none of the above, could you explain?

Question Title

* 5. If so how many patients per year would you estimate fit these criteria at your centre?

Question Title

* 6. Does your centre have access to iron chelation?

Question Title

* 7. If so does your centre routinely iron chelate low-risk MDS patients?

Question Title

* 8. Would a low-risk MDS study compete with any others at your centre? (This study would be designed to capture those MDS patients NOT eligible for COSI/AMADEUS). If yes, which studies?

Question Title

* 9. Do you see any specific challenges (other than recruitment), related to a low-risk MDS transplant study? Are there centre-specific issues we should be aware of, or other comments? If yes, please explain.

Question Title

* 10. Please indicate the name of your centre to prevent duplication. Thank you for your replies!